Our gifting experts are obsessively searching for holiday gifts that are unique, thoughtful and suitable for any budget. Insulin resistance and blood pressure trends are now available on two new Fitbit devices. Nina Raemont is ZDNET's Health and Wearables Editor based in New York City. Insulin resistance and blood pressure trends are coming to the Fitbit Air and Fitbit Edge. These new features are available for Google Health Premium users only.

After four weeks of using the cream, participants lowered the biological age of their skin by about two years on average. A wave of biotech companies is looking to prove that it's possible to slow down the aging process. Mountain View, California-based Rubedo Life Sciences is starting with the most outwardly visible sign: the skin. The company's experimental treatment is showing early promise that it may be able to reduce the appearance of aging, according to data the company presented at the Aging Research and Drug Discovery meeting in Boston earlier this month. In a small clinical trial, Rubedo tested its topical cream on 11 people with atopic dermatitis, an inflammatory skin condition and the most common type of eczema.

The US resurgence of measles is forcing hospitals and health systems to adopt new protocols and procedures to deal with a disease they thought was in the past. John Goldman had not seen a case of measles in 30 years. But since April, the infectious disease specialist with the University of Pittsburgh Medical Center in central Pennsylvania has had dozens of patients come down with the disease. "I never thought I would see this come back," he says. His health system, like others, has had to adapt to a new normal as measles makes a comeback in the United States.

The practice of editing the genes of embryos remains highly controversial and risky, but Origin Genomics founder Cathy Tie argues its a "moral imperative" to address hereditary diseases. When the Chinese scientist He Jiankui announced in 2018 that he had created the first gene-edited babies, the experiment was widely condemned as reckless and premature. It ended with He in prison. But that hasn't stopped the push for gene-edited human embryos, with biotech entrepreneur Cathy Tie arguing that doing so isn't just urgent--it's a "moral imperative." Tie is the 30-year-old founder of Origin Genomics, a company that launched in March with plans to bring gene-edited embryos to IVF clinics.

Follow this section to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW? Smart Alerts: Get notified about major news as it happens. Follow this tag to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW?

Follow this author to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW? Smart Alerts: Get notified about major news as it happens. Dr. Robert Waldinger didn't believe it at first. The idea that loneliness could break down the body--that the quality of your relationships might help decide whether you get coronary artery disease, arthritis, or Type 2 diabetes--struck the psychiatrist as far-fetched.

Health care company Abbott has entered into a partnership to connect Google Health to its Lingo continuous glucose monitor (CGM). According to the press release, this multi-year collaboration will allow users of the over-the-counter Lingo device to see their metabolic data within the Google Health app, which could help a person "make better lifestyle and nutrition choices in the moment." The Lingo data can also be shared with the Google Health Coach, which offers AI-driven recommendations based on an individual's information. Lingo is explicitly intended for adults who are not using insulin. Engadget reported on the growing trend of non-diabetics using continuous glucose monitors back in 2023 and found little research that supported the benefits for that population to track blood sugar spikes so closely.

Image caption, More than 2,000 images were taken of Ruth's skin I don't mind having my photo taken - triple checked and filtered for Instagram - but 70 cameras pointing at me while I'm down to my knickers is a bit daunting. A robotic voice tells me to stay still and close my eyes as I stand in a huge curved scanner while classical music plays in the background. With a flash of light, 2,000 photographs are taken of my body, in the hope of capturing every mark, freckle and mole to analyse for different skin cancers. This full-body scan is happening at a sci-fi-style clinic in Manchester city centre, with me wearing a dressing gown and hexagon-shaped rubber slippers. The millions of data points collected will create a 3D avatar of my body using AI.

The maker of Wegovy and Ozempic, Novo Nordisk, has launched legal action accusing its arch rival Eli Lilly of false advertising in suggesting its weight-loss drugs perform better. The Danish company filed a lawsuit in the US on Tuesday claiming Eli Lilly, which makes Mounjaro and Zepbound, deployed ad campaigns to create the misleading impression that Eli Lilly's medicines are superior. Novo said its rival compared the highest approved doses of its medicines for obesity and type-2 diabetes with lower doses of Novo Nordisk's, while omitting newer, higher-dose options. The BBC has contacted Eli Lilly for comment. The lawsuit comes as Novo and Eli Lilly are locked in battle to dominate the fast-growing weight-loss drug industry, especially in the US, which analysts have estimated could be worth more than $100bn by 2030.

Can you eat too much sugar free candy? But it'll probably just send you running to the bathroom. More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. Sugar-free candy generally replaces sugar with either artificial sweeteners or sugar alcohols. Breakthroughs, discoveries, and DIY tips sent six days a week.